EVOQ Therapeutics is developing immunotherapies focused on improving the lives of individuals fighting autoimmune diseases.
There are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising.
Autoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis, Rheumatoid Arthritis, Primary Biliary Cholangitis, and Systemic Lupus Erythematosus to name a few...
EVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.
Harnessing the human immune system to treat autoimmune disease is extremely challenging. Evoking an appropriate immune response requires a complex set of interactions between the innate and adaptive immune systems.
Fortunately, there is a central figure responsible for orchestrating appropriate immune responses.
That central figure is the dendritic cell (DC). Also known as a “professional” antigen-presenting cells (APCs), dendritic cells specialize in priming different types of effector T cells and directing the immune system either toward a state of self-tolerance or toward the initiation of protective immune activation.
Compared to other APCs, such as B cells and macrophages, dendritic cells are considered to be the most versatile and efficient APCs because of their unique ability to control both immune tolerance and cell-mediated immune activation. They accomplish this using a mix of signals in the form of cell surface receptors and cytokines.
It is for these reasons that denditric cells have long been an attractive target for immunotherapies designed to treat autoimmune disease.
Unfortunately, to date attempts to evoke a truly potent, focused, and sustained response from dendritic cells has produced mixed results.
EVOQ’s breakthrough, proprietary technology unleashes the full potential of dendritic cell mediated immunotherapy.